Meibography and Tear Scan Using the Oculus Keratograph 4
KITCHENER
KITCHENER
Sponsor study identifier
observational
39
1 country
1
Study Start
June 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 2012
Actual (reported)Study Completion
October 2012
Actual (reported)The purpose of this study is to look at both the meibomian glands and the tear film using a new clinical instrument marketed in Canada which was recently acquired by the Centre for Contact Lens Research. These will be compared between two groups of individuals, one group with visible meibomian gland dysfunction (MGD) and one group of individuals with normal meibomian gland appearance. The hypothesis is that there will be a difference between normal individuals and individuals with MGD with respect to the appearance of the meibomian glands and certain tear film attributes.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2012
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2011
Date type not reportedThis date has not been verified as actual or estimated.
June 21, 2011
Actual (reported)June 27, 2011
Actual (reported)October 2012
Actual (reported)October 2012
Actual (reported)November 26, 2013
Actual (reported)Meibomium Gland Dropout Score - Evidence of Meibomian Gland Dysfunction (MGD) Confirmed by Meibograhpy Imaging Using the Keratograph 4 Measured on a Subjective Grading Scale (0-3) (Summing the Score for the Upper and Lower Lids for a Final Scale of 0-6)
Assessments will be made in normal participants (no MGD) and participants with MGD and compared between the two groups at baseline and after the use of a meibomian gland evaluator. The meibomium gland dropout score subjective grading scale: 0 = no loss of mebomium glands 1. = area of meibomium gland loss less than 33% 2. = area of meibomium gland loss between 33% and 67% 3. = area of meibomium gland loss more than 67%.
Before and after the use of a meibomian gland evaluator. Assessments will be separated by a period of at least 10 minutes.
Tear Breakup Time (TBUT). The Time Taken, in Seconds, for the Tear Film to Break up on the Surface of the Cornea.
Measurements will be made in normal participants (no MGD) and participants with MGD and compared between the two groups at baseline and after the use of a meibomian gland evaluator.
Before and after the use of a meibomian gland evaluator. Assessments will be separated by a period of at least 10 minutes.
Tear Meniscus Height (TMH). The Height of the Tear Film Meniscus at the Eyelid Margin.
Assessments will be made in normal participants (no MGD) and participants with MGD and compared between the two groups at baseline and after the use of a meibomian gland evaluator.
Before and after the use of a meibomian gland evaluator. Assessments will be separated by a period of at least 10 minutes.
Non-contact lens wearers will be recruited using CCLR records and advertising approved by the UW Office of Research Ethics
Centre for Contact Lens Research, University of Waterloo
Waterloo, Ontario, N2L 3G1, Canada
Lyndon Jones, PhD
University of Waterloo
39 participants (actual enrollment reported by the registry).
First Submitted
June 21, 2011
First Posted
June 27, 2011
Study Start
June 2011
Date type not reportedThis date has not been verified as actual or estimated.
Evaluation of Dry Eye and Meibomian Gland Dysfunction After Cataract Surgery
Contact the study team to confirm eligibility.
Primary Completion
October 2012
Actual (reported)Study Completion
October 2012
Actual (reported)Last Updated
November 26, 2013
Results First Posted
November 26, 2013
Record last verified: 2013-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: